Drug intelligence / Profile preview

tifentai

Development stage: Unknown
Lead developer: Guizhou Bailing Group Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Tifentai (Y101) is an orally bioavailable small molecule antiviral candidate developed by Guizhou Bailing Enterprise Group Pharmaceutical for the treatment of chronic hepatitis B virus (HBV) infection. It is a synthetic derivative based on the active polyphenolic components of *Penthorum chinense Pursh*, a medicinal herb used in traditional Miao medicine. Tifentai demonstrates the ability to inhibit HBV DNA replication and reduce the levels of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in serum. The drug is designed to provide a novel therapeutic option for patients with chronic hepatitis B, potentially offering a different mechanism of action compared to existing nucleoside/nucleotide analogs. It has been evaluated in Phase I and Phase II clinical trials in China to assess its safety, pharmacokinetics, and antiviral activity.

Other names: 替芬泰

Targets

HBeAg (Hepatitis B e antigen)HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on tifentai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tifentai.

Explore the full profile